IRD

#3317
Opus Genetics, Inc. - Common Stock
3.6 2 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.62
3.62
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-1.90%
Variazione Mensile
-2.69%
Variazione di 6 mesi
-11.27%
Variazione Annuale
-2.69%
Chiusura Precedente
3.6 9
Open
3.6 2
Minimo
3.6 2
Massimo
3.6 2
Volume
45
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Opus Genetics, Inc. (Nasdaq: IRD) filed a Current Report on Form 8-K dated March 4, 2025. The report discloses a significant intellectual property event regarding the Company's product RYZUMVITM.

Key Financial Metrics

This filing is a qualitative disclosure of a legal event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Events

In January 2025, the Company received a Paragraph IV Certification Notice from Sandoz Incorporated (via counsel Winston & Strawn LLP). Sandoz has submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of RYZUMVITM prior to the expiration of six specific patents listed in the Orange Book:

  • U.S. Patent Nos. 9,795,560; 10,278,918; 10,772,829; 11,090,261; 11,844,858; and 11,400,077.

The Notice Letter alleges these patents are invalid, unenforceable, and/or will not be infringed. The filing explicitly states that Sandoz did not challenge two other RYZUMVITM Orange Book patents: U.S. Patent Nos. 12,201,615 and 12,201,616.

Outlook, Risks, and Management Commentary

Management indicated that in response to the ANDA filing, the Company or its commercial partner may choose to file a patent infringement lawsuit to defend intellectual property rights. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to risks described in the Company's Form 10-Q for the quarter ended September 30, 2024.

Investor Verification Checklist

  • Verify the specific claims of invalidity or non-infringement made by Sandoz in the Notice Letter.
  • Confirm whether Opus Genetics or its commercial partner has filed a patent infringement lawsuit and the expected timeline for such action.
  • Assess the remaining term and scope of the two unchallenged patents (Nos. 12,201,615 and 12,201,616) to understand potential market exclusivity.
  • Review the "Risk Factors" section of the most recent Form 10-Q for detailed litigation risks.